
Biotech business Orphazyme, which is based in Copenhagen, Denmark, is planning to raise USD 50m through an American Depositary Shares (ADSs) issuance, it reports in a press release.
The statement also reports that net proceeds from the ADS sales will be spent on the ongoing regulatory approval process for its main candidate arimoclomol, which is a treatment for the neurodegenerative disease, Niemann-Pick disease type C (NPC), in addition to the commercial launch should the drug be approved. The money will also be spent on "general corporate purposes," the press release reads.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app